Biopharma leaders lay out vision for the future of blood cancer treatment

Study of 9/11 first responders finds a higher risk of blood cancer

Taco restaurant sign in San Diego — Adam Feuerstein / STAT

By Adam Feuerstein, Jonathan Wosen, Angus Chen, and Meghana Keshavan

Dec. 8, 2024

(This roundup of news from the ASH 2024 conference first appeared in STAT’s “ASH in 30” newsletter. To get future editions, sign up here.)

When in San Diego, eat tacos. Amazing. Adam, Jonathan, Meghana, and Angus are back for your Sunday ASH rundown. And thanks to everyone who packed the room last night for our STAT @ ASH event.

Industry leaders lay out vision for the future of blood cancer treatment

Biopharma leaders at companies developing blood cancer therapies say we shouldn’t be afraid to use the four-letter word: cure.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

ASH, biotechnology, Cancer, Pharmaceuticals, sickle cell

Submit a correction request Reprints

Adam Feuerstein

Senior Writer, Biotech
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.
Jonathan Wosen

West Coast Biotech & Life Sciences Reporter
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter.
Angus Chen

Cancer Reporter
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His work has been recognized by national Edward R. Murrow awards, the June L. Biedler prize for cancer journalism, and more.
Meghana Keshavan

Biotech Correspondent
Meghana Keshavan covers biotech and contributes to The Readout newsletter.